Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Down 15.3% in January

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 180,273 shares, a drop of 15.3% from the December 31st total of 212,833 shares. Approximately 1.7% of the company’s shares are sold short. Based on an average daily volume of 1,455,659 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 1,455,659 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.7% of the company’s shares are sold short.

Azitra Price Performance

AZTR traded down $0.01 during mid-day trading on Tuesday, hitting $0.23. 592,730 shares of the stock were exchanged, compared to its average volume of 1,558,576. The firm’s fifty day moving average is $0.31 and its two-hundred day moving average is $0.63. Azitra has a 1-year low of $0.22 and a 1-year high of $3.92.

Azitra (NYSEAMERICAN:AZTR) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.12. As a group, sell-side analysts expect that Azitra will post -2.78 earnings per share for the current year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.